Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Sep 10, 2017- Updated results of advanced RCC cohort from Study 111 support continued investigation of first-line use of the combination in ongoing Phase 3 CLEAR study
Eisai Inc. today announced interim results from the advanced renal cell carcinoma (RCC) cohort of Study 111, a Phase 1b/2 study investigating lenvatinib (marketed as Lenvima® in the U.S. and...
-
Sep 10, 2017- Quality of life findings follow presentation of positive results at ASCO 2017 in which lenvatinib was the first systemic therapy to demonstrate non-inferiority to sorafenib in overall survival in first-line treatment of patients with unresectable HCC
Eisai Inc. announced today a delay in the deterioration of five health-related quality of life domains that affect patients' daily lives was observed in patients treated with lenvatinib as...
-
Aug 31, 2017- New data in metastatic renal cell carcinoma from Study 111 evaluating lenvatinib in combination with pembrolizumab to be presented in a proffered paper session on Saturday, Sept. 9 at 10:15 a.m. CEST
Eisai Inc. will present data from its lenvatinib (marketed as Lenvima®) clinical trial program in four difficult-to-treat cancers at the European Society of Medical Oncology (ESMO) 2017 Congress...
-
Aug 28, 2017First kinase inhibitor to show improvement in overall survival in any patient group with RAI-R DTC
Eisai Inc. announced data from a prespecified subgroup analysis, which was published in the Journal of Clinical Oncology, showing treatment with lenvatinib (marketed as Lenvima®) resulted in a...
-
Jul 25, 2017- Filing based on positive pivotal Phase 3 trial demonstrating non-inferior overall survival compared to sorafenib
Eisai Inc. today announced it submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for the first-line use of lenvatinib (marketed as Lenvima®), the...
-
Jun 4, 2017- Lenvatinib is the first systemic therapy to demonstrate non-inferiority to sorafenib in the primary efficacy endpoint of overall survival
Eisai Inc. today announced results from the REFLECT study (Study 304), a Phase 3 trial evaluating lenvatinib (marketed as Lenvima®), the company's multiple receptor tyrosine kinase inhibitor...
-
Jun 3, 2017- Interim results of first evaluable cohort (metastatic endometrial cancer) of Study 111, the Phase 1b/2 trial evaluating lenvatinib in combination with pembrolizumab in selected solid tumors, to be presented at 2017 ASCO Annual Meeting
Eisai Inc. today announced interim results from the first evaluable cohort of Study 111, a Phase 1b/2 study investigating lenvatinib (marketed as Lenvima®), a multiple receptor tyrosine kinase...
-
May 18, 2017- Full results of Study 304, a Phase 3 study evaluating the safety and efficacy of Lenvima® (lenvatinib) as compared to sorafenib in the first-line treatment of patients with unresectable hepatocellular carcinoma, to be presented in an oral presentation on Sunday, June 4 at 8:12 a.m. CDT
Eisai Inc. announced today the presentation of new data and analyses at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting from June 3 – 7 in Chicago. The data to be presented...
-
Mar 28, 2017Research to be presented spans four of the Company's investigational and marketed oncology therapies, both as single agents and in combination
Eisai Inc. announced today 13 presentations of clinical and preclinical research at the American Association for Cancer Research (AACR) 2017 Annual Meeting, April 1 – 5, 2017 in Washington, D.C....
-
Jan 25, 2017
Eisai Inc. today announced positive topline results from the randomized, multicenter Phase 3 trial (Study 304) evaluating the company's multiple receptor tyrosine kinase inhibitor, lenvatinib...